You are here: Industry Insights > Market News

News List

Viroclinics-DDL Changes Name to Cerba Research PharmaSources
March 15, 2024
Viroclinics-DDL proudly announces changing its name to Cerba Research as of the 1st of April 2024.
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology PharmaSources
March 15, 2024
This collaborative effort will leverage ProBioGen's cutting-edge GlymaxX® technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.
ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network PharmaSources
March 13, 2024
The Ginkgo Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD Chunhua Lu
March 11, 2024
Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial.
An Overview to 2023 Pharmaceutical Industry by PharmaSources Experts PharmaSources
March 07, 2024
20 Selected Articles by PharmaSources Experts in 2023
Coriolis Pharma Adds Analytical Ultracentrifugation for Release Testing to its Service Offerings PharmaSources
March 06, 2024
Coriolis Pharma offers Analytical Ultracentrifugation (AUC) for biologics and virus-based drug products from early-stage development to post-market monitoring.
The Narrative of Pharmaceuticals Bestowed with Endorsement and Later Reclaimed by Oblivion by the FDA zhulikou431
March 06, 2024
This document endeavors to compile and elucidate data pertaining to instances where the U.S. FDA, in recent years, has rescinded market approval for pharmaceuticals previously sanctioned.
Cancer-Fighting CAR-T Cell Immunotherapy Potentially Induces New Cancers: An Analysis of Potential Safety Challenges Big Cat of Medical Field
March 06, 2024
Recent reports have indicated that the National Medical Products Administration has addressed the potential carcinogenicity associated with CAR-T cell immunotherapy.
Block-buster Small Molecule Pharmaceuticals Approved by the NMPA in 2023 Yefenghong
March 06, 2024
According to data collated from the National Medical Products Administration (NMPA) official website, a total of more than 80 new drugs were granted inaugural approval within the domestic market.